Sjogren’s syndrome is a chronic autoimmune disorder that primarily targets the exocrine glands—most notably the salivary and tear glands. The immune system, in a misguided response, attacks healthy tissues, leading to inflammation and dysfunction in these glands. This typically results in dry eyes and dry mouth, collectively known as sicca symptoms. The condition can also affect mucosal membranes in the upper respiratory tract, nasal passages, throat, and vaginal area in women, making it a systemic autoimmune disease with widespread impact.
Epidemiology of Sjogren’s Syndrome (2020–2034) in the 7MM
The epidemiological breakdown includes:
-
Total diagnosed prevalent cases
-
Gender-specific occurrence
-
Distribution by type (primary vs. secondary)
-
Severity categorization (mild vs. moderate/severe)
-
Antibody-specific segments (anti-Ro/SSA and anti-La/SSB)
-
Patient population receiving treatment
Key Epidemiological Insights
In 2023, approximately 1.5 million people in the U.S. were diagnosed with Sjogren’s syndrome—a figure expected to rise steadily over time. Among these, the majority were autoantibody-positive, especially those with anti-Ro/SSA and anti-La/SSB antibodies.
Across the 7MM (United States, EU4, UK, and Japan), mild cases were most common, with the UK reporting the highest prevalence among European countries, predominantly in females. The United States had the largest treated population, whereas Japan had the fewest, with about 54,000 patients receiving treatment in 2023. Treatment uptake is forecasted to grow considerably by 2034. For a detailed breakdown, check out the full Sjogren’s Syndrome Market Report.
Sjogren’s Syndrome Market Snapshot
In 2023, the Sjogren’s syndrome market across the 7MM was estimated at approximately USD 2 billion, driven by rising prevalence and increased healthcare focus on autoimmune diseases.
Growth Drivers
-
Improved disease recognition and advancements in therapeutic strategies have significantly enhanced patient management.
-
Ongoing research into genetic, epigenetic, and environmental factors is creating opportunities for innovative drug development.
Ongoing Challenges
-
Currently, there is no curative treatment, with existing therapies focusing on managing symptoms rather than altering disease progression.
-
There remains a critical need for comprehensive clinical research, especially targeting fatigue, dryness, and systemic involvement to improve diagnostic accuracy and therapeutic outcomes.
To explore more, check out this detailed Sjogren’s Syndrome Infographic.
Promising Therapies in Development
Several investigational treatments are being studied to better address both glandular and extra-glandular symptoms:
-
Dazodalibep
-
OXERVATE
-
VAY736
-
CFZ 533
-
RSLV-132
-
SOTYKTU
-
Nipocalimab
-
And other pipeline assets showing potential
These therapies are designed to go beyond symptom control, aiming for more targeted and disease-modifying effects. Learn more about these therapeutic innovations in the complete market forecast.
Major Companies in the Sjogren’s Syndrome Market
Numerous leading pharmaceutical and biotech companies are actively involved in advancing Sjogren’s syndrome research and therapies, including:
-
GlaxoSmithKline, Pfizer, AbbVie, Eli Lilly, Novartis
-
Bristol Myers Squibb, Sanofi, AstraZeneca, Roche, Biogen
-
Resolve Therapeutics, VIELABIO, Daiichi Sankyo, RemeGen, TearSolutions
-
Advanz Pharma, Johnson & Johnson, Amgen, Merck & Co., Takeda
-
Gilead Sciences, Celgene, Vertex Pharmaceuticals, Bayer AG, Boehringer Ingelheim
-
And many others contributing to innovation in this space
For insights on these players and their pipeline developments, view the full Sjogren’s Syndrome Market Infographic.
